PD-1/VEGF bispecific antibody

· Guangzhou Medical University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PD-1/VEGF bispecific antibody, covering 2025-05-20 to 2025-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis [Phase 1, Phase 2]